在ALPK3中,一种新型的化合物异质合体变体诱导过度缩性心肌病变:一个病例报告
Tiange Li1,2, Yuxi Jin1, Rui Liu1,3
1Key Laboratory of Birth Defects and Related Diseases of Women and Children of MOE, Department of Pediatrics, West China Second University Hospital, Sichuan University, Chengdu, China.
Frontiers in cardiovascular medicine
|July 3, 2023
概括
这项研究确定了阿尔法激酶3 (ALPK3) 基因中的新型化合物异构基因变异,该变异发生在患有多变性心肌病症 (HCM) 的患者中. 这些ALPK3基因变异与严重的心脏事件有关,可能需要及时干预.
科学领域:
- 遗传学 遗传学 是一个
- 心脏病学 心脏病学
- 分子生物学分子生物学
背景情况:
- 恶性缩性心肌病 (HCM) 带来心力衰竭,心律失常和突然心脏死亡的风险.
- 预测HCM患者的临床结果至关重要.
- 阿尔法激酶3 (ALPK3) 基因与HCM发展有关.
研究的目的:
- 报告一种与ALPK3基因中新型化合物异质合体变异相关的HCM病例.
- 在一个患有严重临床表现的年轻患者中调查HCM的遗传基础.
- 探索ALPK3变异在HCM病原和临床结果中的潜在作用.
主要方法:
- 进行了全外体测序 (WES) 来识别遗传变异.
- 使用MutationTaster来评估已识别的变种的病原性.
- 使用AlphaFold和瑞士模型进行了蛋白质结构预测.
- 分析了临床数据和成像结果.
主要成果:
- 一名14岁的女性患者出现心力衰竭和突然心脏骤停.
- 在ALPK3基因中,WES确定了从父母遗传的复合异合体变体 (c.3907_3922del和c.2200A>T).
- 这些变种 (p.G1303Lfs*28和p.R734*) 预计会引起疾病,导致截断和非功能性蛋白质.
- 患者表现出左心室缩和心肌标志物升高.
结论:
- 在ALPK3基因中,一种新型化合物异质合体变异与HCM有关.
- ALPK3基因变异,特别是无意义和框架转移类型,可以导致HCM的不良临床结果.
- 早期识别ALPK3变异可能会为风险评估和管理提供信息,可能包括需要植入式心脏转换器除器 (ICD).
相关概念视频
Cardiomyopathy III: Hypertrophic Cardiomyopathy
16
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
16
Cardiomyopathy II: Dilated Cardiomyopathy
11
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
11
Cardiomyopathy I: Introduction and Classification
19
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
19
Cardiomyopathy IV: Restrictive Cardiomyopathy
12
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
12


